Edition:
United States

Soligenix Inc (SNGX.OQ)

SNGX.OQ on NASDAQ Stock Exchange Capital Market

1.34USD
17 Aug 2018
Change (% chg)

$-0.03 (-2.19%)
Prev Close
$1.37
Open
$1.35
Day's High
$1.37
Day's Low
$1.34
Volume
12,669
Avg. Vol
24,824
52-wk High
$3.70
52-wk Low
$0.91

Chart for

About

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical... (more)

Overall

Beta: 0.23
Market Cap(Mil.): $23.69
Shares Outstanding(Mil.): 17.68
Dividend: --
Yield (%): --

Financials

  SNGX.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -0.89 -- --
ROI: -225.32 2.89 12.63
ROE: -225.32 1.65 14.82

BRIEF-Soligenix Reports Q1 Loss Per Share Of $0.27

* SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND FIRST QUARTER 2018 FINANCIAL RESULTS

May 11 2018

BRIEF-Soligenix Receives Orphan Drug Designation From The European Commission For Rivax For Prevention Of Ricin Poisoning

* SOLIGENIX RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR RIVAX® FOR PREVENTION OF RICIN POISONING Source text for Eikon: Further company coverage:

Mar 22 2018

Earnings vs. Estimates